Alucent BIOMEDICAL

Press Release

Alucent Biomedical Announces First Patient Enrolled in First in Human Natural Vascular Scaffolding Clinical Trial

Multicenter ACTIVATE II Study to Enroll up to 50 Patients in Australia

SALT LAKE CITY – April 12, 2022 – Alucent Biomedical Inc. announced that it has enrolled the first patient in ACTIVATE II, an Australia-based First-in-Human clinical trial to evaluate the safety and efficacy of its revolutionary Natural Vascular Scaffolding (AlucentNVS) technology. The therapy is designed to open vessels and maintain patency without the use of permanent implants for the treatment of peripheral artery disease (PAD) of the lower extremities. PAD, a painful and debilitating condition, affects more than 200 million people globally.

The Alucent NVS Vessel Restoration System with Photoactivated Linking combines standard angioplasty with linking of the structural proteins in the wall of a blood vessel. The intervention is designed to deliver restoration of the vessel's lumen and sustained improvement of blood flow, without the introduction of a foreign implant, such as a metallic stent. Absent a rigid foreign material, the arterial wall has the potential to retain its natural functionality and flexibility while avoiding traditional complications of permanent stents. Alucent NVS photoactivated linking is also designed to mitigate the well-known adverse effects of angioplasty, such as vessel recoil. Sustained, improved blood flow is expected to result in pain relief, limb preservation, and an improved quality of life for patients.

The first patient in the ACTIVATE II study was enrolled by Dr. Chris Delaney at Flinders Medical Centre in Adelaide. In total, the trial will enroll up to 50 subjects with up to 12 research sites, which will also include Prince of Wales Hospital in Sydney, The Alfred Hospital in Melbourne, Royal Perth Hospital, and Sir Charles Gairdner Hospital in Perth. The primary endpoints of the study are freedom from composite investigational-device, procedure-related Major Adverse Events, Primary Patency as assessed by Doppler Ultrasound, and freedom from clinically driven target lesion revascularization (CD-TLR) at one year.

ACTIVATE II follows the completion of enrollment for ACTIVATE I safety study of AlucentNVS within the United States. Pre-clinical testing of AlucentNVS in animal studies has shown acute and long-term safety and patency without the pro-inflammatory and mechanical risks of placing a rigid foreign implant into the blood vessel.

"PAD is a difficult condition affecting so many people worldwide, and its current treatments have significant shortcomings," said Dr. Myles Greenberg, Alucent Biomedical's CEO. "We want to change that by offering a whole new way to treat these patients with AlucentNVS. Alucent's novel approach has the potential to change the way PAD is managed in the future."

About Alucent Biomedical
Alucent Biomedical is a privately held company dedicated to developing and commercializing its breakthrough Natural Vascular Scaffolding (AlucentNVS) technology for the treatment of vascular disease. AlucentNVS is designed to use photoactivated protein linking of the vessel's native structural proteins to open vessels and keep them open – without the use of permanent implants. Alucent Biomedical was founded by the Avera Research Institute, part of the multistate Avera Health System, in 2017. For more information, visit alucentbiomedical.com.

MEDIA CONTACT:
Joe Duraes
Pazanga Health Communications
jduraes@pazangahealth.com
917-687-6419

###